NSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹20.26
- Market cap
- ₹111.8 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 46.1×Sector 46.5×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Other board meeting date announcements
All →Jetking Infotrain Board Meeting Date
Jetking Infotrain has scheduled a board meeting on November 4, 2026 to consider unaudited quarterly and half-year results. The trading window remains closed until 48 hours after the results announcement.
Metropolis Healthcare Board Meeting Date
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Aelea Commodities Board Meeting Date
Aelea Commodities has scheduled a board meeting for 2 November 2026 to consider half-year results and other items. The agenda includes an additional independent director, a director resignation, and business expansion and capex.
R Systems International Board Meeting Date
R Systems International will hold a board meeting on 3 November 2026 to consider quarterly and nine-month results to September 2026. The trading window remains closed until 48 hours after the results are declared.
Onida Electronics Board Meeting Date
Onida Electronics schedules a 3 November 2026 board meeting for Q2 and half-year results and ESOP share allotment. Trading window stays closed until 48 hours post-results.
Platinum Industries Board Meeting Date
Platinum Industries Ltd intimated a board meeting on November 4, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window closed from October 1, 2026.